Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine

Patients with diabetes and coexistent coronavirus disease 2019 (COVID-19) have a higher risk of COVID-19 complications. Therefore, it is critical that sustained and effective immunogenicity against COVID-19 is achieved in such patients. This study evaluates the antibody response for 56 days after th...

Full description

Saved in:
Bibliographic Details
Published in:Diabetology international 2022-10, Vol.13 (4), p.637-643
Main Authors: Rangsrisaeneepitak, Vimonsri, Porntharukchareon, Thachanun, Dechates, Bothamai, Sirisreetreerux, Supamas, Tawinprai, Kriangkrai
Format: Article
Language:English
Subjects:
Antibodies
Antibody response
Coronaviruses
COVID-19
COVID-19 vaccines
Diabetes
Diabetes mellitus (non-insulin dependent)
Endocrinology
Immune response
Immunogenicity
Immunoglobulin G
Medicine
Medicine & Public Health
Metabolic Diseases
Original
Original Article
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with diabetes and coexistent coronavirus disease 2019 (COVID-19) have a higher risk of COVID-19 complications. Therefore, it is critical that sustained and effective immunogenicity against COVID-19 is achieved in such patients. This study evaluates the antibody response for 56 days after the first dose of the AZD1222 vaccine in subjects with and without diabetes to assess the potential risk of delaying the second dose. This study included 282 people who received one dose of AZD1222. The geometric mean concentration of antibodies specific for severe acute respiratory syndrome coronavirus 2 IgG at 56 days was significantly ( P  
ISSN:2190-1678
2190-1686
DOI:10.1007/s13340-022-00582-1